Your Comprehensive 2025 Guide to Psoriasis Treatments

Summary

Your Comprehensive 2025 Guide to Psoriasis Treatments provides an up-to-date, evidence-based overview of psoriasis management, integrating advances in clinical practice and research to support optimal patient care. Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting millions worldwide, characterized by erythematous plaques and systemic comorbidities. This guide is notable for its comprehensive scope, covering disease assessment, trigger identification, comorbidity screening, and a broad spectrum of treatment modalities, including topical, phototherapy, systemic, and biologic therapies tailored to both adult and pediatric populations.
Developed in alignment with the Living Cochrane review, the 2025 guideline emphasizes continual updating based on emerging evidence to maintain clinical relevance. It highlights recent innovations such as novel topical biologics, advancements in phototherapy techniques, and an expanded array of FDA-approved systemic and biologic agents targeting key immunological pathways like IL-17, IL-23, and TNF-α. These therapies have revolutionized psoriasis management by improving efficacy, safety, and patient quality of life. Furthermore, the guide addresses important safety considerations, including infection risks associated with biologics and nuanced decision-making around their use in special populations such as pregnant patients.
This resource also explores patient-centered challenges including treatment adherence, psychosocial impacts, and the integration of complementary and alternative medicine (CAM). It recognizes the profound emotional and social burdens psoriasis imposes, with up to 98% of patients reporting psychological effects often under-addressed in routine care. The guide advocates for multidisciplinary approaches incorporating mental health support and patient education to enhance adherence and outcomes. Additionally, it discusses emerging concepts such as the International Psoriasis Council’s “topical failure” definition and promising new treatments demonstrated in clinical trials, underscoring ongoing efforts to close therapeutic gaps.
Overall, Your Comprehensive 2025 Guide to Psoriasis Treatments serves as an essential reference for clinicians, researchers, and patients by synthesizing current knowledge and addressing controversies in safety and management strategies. Its living guideline model ensures adaptability to future advances, aiming to deliver personalized, effective, and holistic psoriasis care in the years ahead.

Overview

The 2025 guideline for psoriasis treatment provides a comprehensive framework divided into six key sections addressing overall disease management. These sections include measuring disease severity, identifying and assessing triggers, screening for comorbidities, and implementing treatment strategies involving topical, phototherapy, systemic, and biologic therapies. This guideline emphasizes the importance of recognizing differences between pediatric and adult psoriasis and offers a valuable reference to optimize clinical care across patient populations.
Developed in alignment with the Living Cochrane review, the recommendations are based on current and emerging evidence, with plans for continual updates as new data become available. This dynamic approach ensures that clinical guidance remains relevant, especially regarding specific clinical presentations and comorbid conditions. The methodology incorporated an extensive literature search utilizing Medical Subject Heading (MeSH) terms related to various forms of psoriasis and therapeutic modalities, including narrowband ultraviolet B (NB-UVB), excimer laser, and other phototherapies, ensuring a thorough evidence base for treatment options.
Safety considerations for biologic therapies, a cornerstone of systemic psoriasis management, are addressed with caution due to limited definitive data, particularly concerning use during pregnancy. Studies assessing maternal exposure to biologics such as secukinumab have found fetal outcomes comparable to the general population, although the absence of controlled trials precludes firm safety conclusions. Clinical decisions on biologic use in pregnancy must therefore be individualized, and practice guidelines may vary. Moreover, large cohort studies have identified differential risks of serious infections associated with various biologics, noting increased risk with infliximab and adalimumab, but reduced or no increased risk with others like ustekinumab and secukinumab, which is critical for informing patient-specific therapy choices.
Recent developments in psoriasis care discussed among leading experts highlight ongoing gaps in treatment and evolving concepts such as the International Psoriasis Council’s definition of “topical failure.” Clinical trials, including the ICONIC-ADVANCE and ICONIC-LEAD studies, have demonstrated sustained disease clearance and favorable safety profiles for emerging treatments like icotrokinra in both adults and adolescents, signaling promising advancements in the therapeutic landscape.

Pathophysiology

Psoriasis is a complex immune-mediated disease characterized by a pathological network of interactions between immune cells and skin cells, particularly keratinocytes. Central to its pathogenesis is the activation of both innate and adaptive immune pathways, leading to the uncontrolled proliferation of keratinocytes, acanthosis, neovascularization, and substantial infiltration of immune cells in the skin.
A key feature of psoriasis is the involvement of dendritic cells, T helper 17 (Th17) cells, and keratinocytes forming a pathogenic triad. Dendritic cells produce proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-23 (IL-23), which promote the differentiation of naïve T cells toward the Th17 lineage. Th17 cells, in turn, secrete cytokines including interleukin-17 (IL-17), interleukin-22 (IL-22), and TNF-α, which are critical drivers of psoriatic inflammation.
Interleukin-1 alpha (IL-1α) plays a pivotal role in the formation of T cell–antigen presenting cell (APC) clusters within the dermis, creating an extra-lymphoid microenvironment that facilitates close interactions among dendritic cells, T cells, and macrophages to elicit immune responses. IL-1 signaling is essential for priming APCs and cooperates with IL-23 in inducing IL-17 production by T cells, further amplifying the inflammatory cascade. The characteristic immune cell infiltrate in psoriasis lesions includes a mixed population of CD4+ and CD8+ T cells in the dermis, with an exclusive CD8+ T cell presence in the epidermis, reflecting the disease’s nature as a T cell-mediated condition with a combined Th1/Th17 cytokine milieu.
Cutaneous tissue-resident memory T (TRM) cells also contribute to disease persistence and inflammation. Cytokines such as transforming growth factor-beta (TGF-β) act as negative regulators of CD8+ T cell function, limiting effector responses, while other TRM-derived cytokines including IL-15 and IL-7 play significant roles in sustaining inflammatory skin conditions like psoriasis.
Genetic predisposition influences disease susceptibility and severity. Several risk loci have been identified, including HLA-Cw6 (involved in antigen presentation), IL12B and IL23R (in cytokine signaling), and multiple genes regulating NF-κB signaling such as TNFAIP3 and RELA. These genetic factors contribute to the dysregulation of immune responses and keratinocyte activation observed in psoriatic skin.
Importantly, psoriasis shares pathogenic mechanisms with other inflammatory conditions, exemplified by its increased association with type 2 diabetes. Genome-wide studies have uncovered shared genetic loci linked via the NF-κB inflammatory pathway, highlighting the systemic nature of psoriasis-associated inflammation.
Advances in understanding the molecular and cellular pathways underlying psoriasis have revolutionized treatment strategies. Targeted biologic therapies selectively inhibit key cytokines like IL-17, IL-23, and TNF-α, offering more effective disease control compared to traditional generalized immunosuppressants.

Treatment Modalities

Psoriasis treatment in 2025 involves a multifaceted approach, ranging from topical therapies for mild to moderate disease to systemic and biologic agents for more severe cases. The treatment landscape has expanded considerably, with advancements in formulations, delivery systems, and novel therapeutic classes enhancing both efficacy and safety.

Topical Therapies

Topical treatments remain the cornerstone for managing mild to moderate psoriasis and are often the first line of therapy prescribed by primary care physicians. Combination products, such as calcipotriol and betamethasone dipropionate, have demonstrated superior efficacy compared to monotherapy with either agent alone, achieving a mean 74% reduction in Psoriasis Area and Severity Index (PASI) scores at four weeks. These combinations also tend to have fewer adverse events when used concomitantly or sequentially. Other topical agents include corticosteroids, emollients, salicylic acid, anthralin, and coal tar, which can be used alone or in combination to optimize outcomes.
Recent developments have introduced innovative topical biologics, including IL-4 inhibitors, aiming to provide biologic benefits without systemic exposure. Additionally, new steroid-free topical agents such as roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, and tapinarof, an aryl hydrocarbon receptor agonist, received FDA approval in 2022. These once-daily creams offer non-oily, non-sticky formulations that may improve patient adherence and long-term treatment success. The 2019 FDA approval of DUOBRII®, a lotion combining halobetasol and tazarotene, highlights the trend toward combination topical preparations for plaque psoriasis.

Phototherapy

Phototherapy continues to be a valuable option for moderate-to-severe psoriasis. Narrowband ultraviolet B (NB-UVB) is the preferred modality due to its favorable safety and efficacy profile, with broadband UVB (BB-UVB) as an alternative when NB-UVB is unavailable. Application of thin layers of emollients prior to phototherapy sessions can increase treatment effectiveness and reduce UV-induced erythema, though thick emollient application should be avoided to prevent diminished UVB transmission.
Coal tar preparations, often used in conjunction with phototherapy, should not be applied immediately before NB-UVB due to potential reduction in efficacy. Combining phototherapy with agents such as fumaric acid esters (FAE) may accelerate clinical response without impacting long-term outcomes. Maintenance phototherapy can be considered to sustain clinical improvement after initial treatment courses.

Systemic Therapies

For moderate to severe psoriasis, systemic treatments are often required. Methotrexate remains a recommended oral non-biologic medication with established efficacy, though it is generally less effective than biologics such as adalimumab and infliximab. Methotrexate use requires monitoring for hepatotoxicity, with newer non-invasive tests available to evaluate for liver fibrosis. Systemic retinoids, like acitretin, are effective particularly in guttate, pustular, and palmoplantar psoriasis and have the advantage of lacking immunosuppressive effects, making them suitable for transplant patients.
Systemic corticosteroids are generally avoided due to the risk of triggering severe psoriasis flares, such as pustular psoriasis, and the potential for serious adverse effects including liver cirrhosis with prolonged use.

Biologic Agents

The therapeutic armamentarium for psoriasis has been greatly expanded with the approval of 11 FDA-approved biologic agents, targeting various immune pathways. These agents offer targeted immunomodulation, which has significantly improved both safety and efficacy profiles. Biologics such as etanercept and ustekinumab are approved for use in pediatric populations aged four years and older and twelve years and older, respectively. Many biologics are also used off-label and may be combined with systemic or topical therapies to enhance treatment response.

Other Modalities and Considerations

Complementary and alternative medicine (CAM) remains common among psoriasis patients, including traditional Chinese medicine, herbal therapies, dietary supplements, and climatotherapy, though these modalities require further rigorous evaluation. Patient adherence remains a critical determinant of treatment success across all modalities, and strategies to improve compliance are essential.

Treatment Guidelines and Protocols

The management of psoriasis has been extensively guided by updated clinical guidelines that integrate the latest evidence and expert consensus. The 2021 AAD/National Psoriasis Foundation (NPF) guideline update on topical treatments for plaque psoriasis, which reviewed literature from 2008 to 2017, remains a cornerstone in treatment protocols and has been well-received and promoted by key organizations including the American Academy of Family Physicians, the American Academy of Dermatology (AAD), and the NPF. This guideline update is comprehensive, dividing management into six sections that cover overall disease management, measuring disease severity, assessing triggers, screening for comorbidities, and treatment approaches using topical, phototherapy, systemic, and biologic therapies.
Topical therapies continue to be recommended as first-line treatment for patients with mild to moderate psoriasis and can be safely initiated by primary care providers, who often serve as the first point of contact for patients. However, patients presenting with more severe or refractory disease symptoms typically require evaluation by dermatologists for consideration of systemic treatments. Adherence to topical and oral therapies remains a challenge, with studies assessing compliance through both self-reporting and objective methods revealing various patient-related barriers. Approaches encouraging nonjudgmental communication and addressing patients’ beliefs and treatment challenges are suggested to improve adherence.
For moderate-to-severe psoriasis, systemic treatments including biologic therapies have revolutionized disease management over the last decade. Biologics, which target specific immune pathways such as IL-17, TNF-α, and IL-23, offer high efficacy and a favorable safety profile without evidence of cumulative organ-specific toxicity. The British Association of Dermatologists updated their clinical practice guidelines for biologic therapy in 2020, emphasizing that initiation and supervision of biologics should be conducted by specialist physicians experienced in psoriasis care. Biologics are particularly suitable for patients who have not responded adequately or have experienced adverse effects from other therapies.
Recent regulatory approvals and innovations have expanded the therapeutic landscape in 2025, highlighting the importance of individualized treatment plans aimed at optimal therapeutic targets. Novel treatments such as apremilast and deucravacitinib, along with newer biologics, are addressing unmet needs related to faster onset of action, patient convenience, and minimized side effects.
Psychosocial considerations have also been integrated into treatment guidelines, recognizing that up to 98% of psoriasis patients experience emotional or psychological impacts, yet only a small fraction seek help. The COVID-19 pandemic has further complicated access to care and increased mental health challenges among patients, necessitating improved clinician training and resources to evaluate and manage the psychosocial burden of psoriasis effectively.

Safety, Adverse Effects, and Monitoring

The safety profiles of psoriasis treatments, particularly biologic therapies, have been extensively studied to understand their long-term risks and guide clinical management. A large cohort study involving 44,239 psoriasis patients in France evaluated serious infection risks associated with different biologics over a median follow-up of 12 months. This study found an increased risk of serious infections with infliximab (weighted hazard ratio [wHR] 1.79, 95% CI 1.49–2.16) and adalimumab (wHR 1.22, 95% CI 1.07–1.38), whereas ustekinumab showed a reduced risk (wHR 0.79, 95% CI 0.67–0.94). No increased infection risk was associated with secukinumab, ixekizumab, brodalumab, or guselkumab.
Screening for infectious diseases such as tuberculosis is a crucial step before initiating biologic therapies due to the immunosuppressive effects of these agents. Healthcare providers generally recommend testing for latent infections to minimize complications during treatment. Patients should discuss both short- and long-term side effects and risks with their providers to ensure informed decisions about biologic use.
Concerns have also been raised regarding major adverse cardiovascular events (MACEs) in patients treated with anti-interleukin (IL)-12/23 agents. Meta-analyses of randomized controlled trials have sought to clarify these risks, highlighting the importance of cardiovascular monitoring in patients undergoing biologic therapy.
Adherence to psoriasis treatments, including topicals, systemic agents, and phototherapy, significantly influences efficacy and safety outcomes. Studies show that patient preferences, treatment vehicle, and disease location (e.g., scalp or nails) affect adherence rates. For example, less greasy formulations such as foams or shampoos are preferred for the scalp, facilitating better compliance. Direct questioning and objective measures of adherence reveal variability among patients, emphasizing the need for tailored

Adherence and Patient Challenges

Adherence to psoriasis treatment remains a significant challenge, with patients often struggling to maintain consistent use of prescribed therapies. A Cochrane systematic review estimated that adherence in chronic diseases is approximately 50%, and similar trends have been observed in psoriasis. For example, an 8-week clinical trial using objective adherence measures found a decrease from 84.6% to 51% in topical treatment adherence, with the most notable gaps occurring during weekends. Another study assessing adherence through self-reporting and objective methods among 294 patients revealed varying compliance with topical and oral therapies, highlighting the complexity of maintaining treatment regimens in outpatient settings.
Qualitative research has enriched the understanding of adherence by exploring patient perspectives and the multifaceted barriers they face. Employing a nonjudgmental approach that acknowledges these barriers encourages patients to discuss beliefs about psoriasis, medication management, and how treatments fit into their daily lives, which are critical factors influencing adherence. These insights emphasize the importance of personalized communication and support from healthcare providers to improve treatment outcomes.
Psychosocial challenges compound difficulties in treatment adherence. Up to 98% of patients report that psoriasis affects their emotional or psychological well-being, yet only 18% receive psychological support. This care gap is partly due to limited awareness of available services and the high prevalence of alexithymia—found in approximately 25% of patients with psoriasis—which impairs their ability to recognize and articulate emotions. Consequently, patients may underreport psychological distress, complicating timely identification and intervention. Moreover, patients frequently trivialize their condition, perceiving it as non-life-threatening and therefore not warranting medical attention, which further delays appropriate care.
The COVID-19 pandemic has intensified these challenges by exacerbating mental health issues and limiting healthcare access. Social distancing, self-isolation, and shielding—especially among those on immunosuppressive treatments—have contributed to increased rates of anxiety, depression, poor treatment compliance, and reduced healthcare attendance. Clinicians require enhanced training and resources to actively assess and address the psychosocial impacts of psoriasis, recognizing that comprehensive care must include multidisciplinary psychodermatology services.
Understanding patient illness perceptions is also crucial. Limited patient knowledge about psoriasis and its comorbidities often leads to anxiety and emotional distress. Educational interventions grounded in theory-based materials can improve disease comprehension and reduce psychological burden. Since psoriasis affects more than just physical health—impacting social relationships, self-esteem, and quality of life—it is essential that healthcare providers acknowledge and manage the broader psychosocial effects to optimize patient outcomes.

Complementary and Alternative Therapies

Complementary and alternative medicine (CAM) is widely used by patients with psoriasis, encompassing a diverse range of modalities such as traditional Chinese medicine (TCM), herbal therapies, dietary supplements, climatotherapy, and mind/body interventions. Recent systematic reviews and clinical trials have explored the efficacy of several CAM approaches, identifying specific therapies with promising results for psoriasis management.
Among the CAM therapies supported by the most robust clinical evidence are indigo naturalis, curcumin, dietary modifications, fish oil supplementation, meditation, and acupuncture. Indigo naturalis, a herbal extract derived from the indigo plant, has demonstrated anti-inflammatory effects beneficial for psoriatic lesions. Curcumin, a bioactive compound from turmeric, shows potential both as a topical and systemic agent, often enhancing conventional treatments and contributing to improved clinical outcomes. Dietary interventions, including adjustments that reduce pro-inflammatory foods and incorporate beneficial nutrients such as omega-3 fatty acids from fish oil, have also been linked to reductions in psoriasis severity.
Mind/body techniques such as meditation and acupuncture are gaining attention for their role in alleviating psoriasis symptoms, possibly through stress reduction and immune modulation. Meditation has been associated with improved psychological well-being and decreased disease flare-ups, while acupuncture protocols have shown preliminary positive clinical effects, though further randomized controlled trials are warranted to confirm long-term efficacy and safety.
Climatotherapy, which involves exposure to specific environmental conditions such as sunlight and mineral-rich waters, remains another CAM approach explored in psoriasis care. Although less extensively studied in recent trials, it is recognized for its historical use and patient-reported benefits, particularly when combined with other therapies.
Despite encouraging preliminary results, the need for additional well-designed randomized controlled trials is emphasized to establish definitive therapeutic roles and safety profiles for these CAM treatments in psoriasis. Practitioners are advised to consider patient preferences and to provide guidance on the integration of CAM with conventional therapies to optimize adherence and clinical outcomes.

Psychosocial Impact and Quality of Life

Psoriasis is a chronic inflammatory skin condition that profoundly affects patients’ psychosocial well-being and overall quality of life (QoL). The psychosocial impact of psoriasis extends beyond the physical manifestations of the disease, influencing emotional health, social interactions, and daily functioning. Despite this significant burden, these effects are often underestimated by healthcare providers, highlighting the need for comprehensive care approaches that integrate psychosocial support.

Emotional and Social Challenges

Patients with psoriasis frequently experience social stigmatization due to visible lesions, especially when they occur on exposed areas of the skin. This can lead to impaired self-esteem and difficulties in interpersonal relationships, contributing to emotional burdens such as anxiety and depression. The fear of judgment and self-consciousness often results in social withdrawal and isolation, which can exacerbate feelings of loneliness and negatively affect mental health. Open communication about these emotional challenges—with loved ones or therapists—can alleviate some of this burden and foster greater understanding and support.

Health-Related Quality of Life

Health-related quality of life (HRQOL), a specific subset of QoL focusing on physical, psychological, and social well-being related to health status, is significantly compromised in individuals with psoriasis. The disease limits daily activities, occupational performance, and sexual functioning, with a notably stronger impact on psychosocial domains than on physical activities. The chronic, relapsing nature of psoriasis further contributes to this diminished QoL by imposing ongoing stress and uncertainty on patients.

Barriers to Psychological Support

A considerable challenge in addressing the psychosocial needs of patients with psoriasis is the high prevalence of alexithymia—characterized by difficulty in identifying and expressing emotions—which affects about 25% of patients. This condition hampers effective communication between patients and healthcare providers, complicating the identification of psychological distress and the provision of appropriate mental health interventions. Additionally, patients may trivialize their condition, perceiving it as non-life-threatening and thus less deserving of medical attention, which further limits psychosocial support.

Impact of the COVID-19 Pandemic

The mental health crisis triggered by the COVID-19 pandemic has intensified the psychosocial challenges faced by psoriasis patients. Social distancing, self-isolation, and shielding measures—particularly for those on immunosuppressive therapies—have led to increased rates of anxiety, depression, and poor treatment adherence. Access to healthcare services has also been restricted, further impeding the management of both dermatological and psychological aspects of the disease.

Strategies for Improvement

Addressing the psychosocial impact of psoriasis requires a nonjudgmental, patient-centered approach that recognizes and discusses barriers to treatment adherence and emotional well-being. Encouraging open dialogue about patients’ beliefs, medication management, and the integration of treatment into daily life can enhance adherence and overall outcomes. Providing education, psychosocial interventions, and supportive resources is essential to improve the quality of life for those living with psoriasis.

Recent Advances and Future Directions

Over the past several years, the landscape of psoriasis treatment has evolved significantly, driven by new therapeutic options and an improved understanding of the underlying immunopathogenesis of the disease. Since 2017, topical treatment options have expanded rapidly, including combination products that incorporate older medications with newer formulations, as well as the introduction of entirely new drug classes, enhancing the therapeutic arsenal available for patients with psoriasis.
One of the most notable advances in systemic therapy has been the rise of biologic agents targeting specific immune pathways implicated in psoriasis. These biologics, administered via injection or intravenous infusion, selectively inhibit cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), interleukin-12/23, and interleukin-23, which play central roles in the inflammatory cascade driving psoriasis and psoriatic arthritis. The advent of these agents has revolutionized management, offering high efficacy with improved safety profiles and minimal cumulative organ toxicity. Currently, there are eleven FDA-approved biologic therapies for psoriasis, with additional agents in development, signaling a robust and expanding therapeutic pipeline.
Complementing these targeted treatments, growing evidence supports the use of complementary and alternative medicine (CAM) therapies as adjunctive or alternative options. A comprehensive review of randomized controlled trials from 2018 to 2024 highlighted several CAM approaches with promising clinical benefits, including indigo naturalis, curcumin, dietary modifications, fish oil supplementation, meditation, acupuncture, and balneotherapy. These therapies, while still requiring further rigorous validation, offer patients additional avenues for symptom relief and holistic management.
At the immunological level, recent research has elucidated complex interactions between various cytokines and immune cells in psoriasis pathogenesis, such as the critical roles of IL-1α, IL-15, IL-7, and TGF-β in modulating T cell responses and maintaining cutaneous immune homeostasis. This deeper mechanistic insight is informing the development of novel therapeutic targets and personalized treatment strategies.
Looking forward, the guideline development groups remain committed to continuously updating recommendations as new evidence emerges from ongoing clinical trials and research. The adoption of a living guideline model ensures that clinicians and patients will benefit from timely access to the latest advances in psoriasis care, including tailored approaches for clinical and comorbid situations. Together, these advances mark a step toward more precise, effective, and patient-centered management of psoriasis in the coming years.

Living with Psoriasis

Psoriasis is a chronic, inflammatory, multisystem disease that significantly impacts patients’ daily lives beyond the physical symptoms of the skin. Living with psoriasis involves managing not only the visible plaques but also the psychological, social, and emotional challenges associated with the condition. Health-related quality of life (HRQOL) is often severely affected, with psoriasis limiting daily activities, occupational and sexual functioning, and social interactions. Psychosocial impairments tend to be more profound than physical limitations, contributing to emotional distress and social isolation for many patients.
Patient education is paramount in living with psoriasis, as understanding the chronic nature of the disease and potential comorbidities empowers patients to engage effectively in their treatment plans. Individuals with mild disease may be managed with topical therapies, while those with extensive or debilitating symptoms might require phototherapy or systemic treatments such as methotrexate or newer targeted therapies. Comprehensive education also involves raising awareness about the importance of medication adherence, which is critical for achieving optimal therapeutic outcomes. However, medication nonadherence remains a common challenge, often due to the burdensome nature of self-management, competing priorities, limited personal resources, and psychological factors such as self-regulation failure.
Emotional wellness plays a vital role in the treatment journey. Open communication about the emotional and psychological challenges of living with psoriasis can alleviate feelings of isolation and foster support from loved ones and healthcare professionals. Nevertheless, identifying patients in need of psychological support can be difficult, as approximately 25% of individuals with psoriasis exhibit alexithymia—a reduced ability to recognize and describe internal emotions—making it harder for them to express their feelings and seek help. To address these multifaceted needs, support programs that connect patients with mentors and the wider psoriasis community have been developed. These programs provide information on goal-setting, healthy living, and emotional support, reinforcing that psoriasis is “more than skin deep” and that emotional well-being is an integral part of care.
Healthcare providers are encouraged to recognize the complex comorbidities associated with psoriasis and collaborate with patients and multidisciplinary teams to ensure appropriate screening, treatment, and psychological support. Through education, emotional support, and tailored treatment strategies, individuals living with psoriasis can better manage their condition and improve their overall quality of life.

The content is provided by Jordan Fields, Scopewires